Nasdaq · CIK 0001674632
BBNX Beta Bionics, Inc.
Insider trading from SEC Form 4. Last filing 8 d ago. Close $17.63 on Oct 9, 2026, +99% from the 52-week low and -45% from the high.
In brief
Beta Bionics, Inc. (BBNX) has 103 SEC Form 4 filings on file from 11 insiders, the latest filed on Oct 5, 2026. In the last 90 days insiders made 0 open-market buys worth $0 and 13 open-market sells worth $3.0M, net -$3.0M.
65 open-market trades have been scored at BBNX. The newest: Mark Hopman (Chief Commercial Officer) sold $7,015 of stock on Oct 1, 2026, filed Oct 5, 2026, scored 3 (weak), under a 10b5-1 plan. The largest of the 50 shown: Mark Hopman (Chief Commercial Officer) sold $681k on Sep 9, 2026, scored 41 (moderate), under a 10b5-1 plan. 2 insiders sold within 14 days of each other around Oct 1, 2026.
25 Form 144 notices of planned sales are on file, the latest filed Oct 1, 2026.
Last 90 days
Net insider value
-$3.0M
more sold than bought
Buys
0
$0 by 0 insiders
Sells
13
$3.0M by 6 insiders
Insiders on file
11
with a Form 4 at this company
Price and insider trades, last year
BBNXOct 9, 2026 · close 17.63
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Beta Bionics, Inc., scored: the newest 50 of 65.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 3Weak | Mark Hopman Chief Commercial Officer sell | $7,015 370 shares | -1% | +113% from low-41% from high | |
| 26Weak | Christy Jones director sell | $148k 6,430 shares | -25% | +157% from low-29% from high | |
| 40Moderate | Mark Hopman Chief Commercial Officer sell | $665k 35,994 shares | -29% | +97% from low-46% from high | |
| 40Moderate | Mark Hopman Chief Commercial Officer sell | $620k 30,779 shares | -35% | +150% from low-31% from high | |
| 17Weak | Mike Mensinger Chief Product Officer sell | $58k 2,650 shares | -1% | +150% from low-31% from high | |
| 10Weak | Mark Hopman Chief Commercial Officer sell | $12k 775 shares | -1% | +89% from low-48% from high | |
| 41Moderate | Mark Hopman Chief Commercial Officer sell | $681k 36,870 shares | -30% | +97% from low-46% from high | |
| 30Weak | Sean Saint President & CEO sell | $113k 5,641 shares | -1% | +125% from low-38% from high | |
| 40Moderate | Mark Hopman Chief Commercial Officer sell | $102k 5,327 shares | -4% | +119% from low-39% from high | |
| 39Weak | Mike Mensinger Chief Product Officer sell | $84k 4,375 shares | -2% | +119% from low-39% from high | |
| 48Moderate | Stephen Feider Chief Financial Officer sell | $128k 6,675 shares | -4% | +119% from low-39% from high | |
| 54Moderate | Sean Saint President & CEO sell | $322k 16,867 shares | -4% | +119% from low-39% from high | |
| 39Weak | Steven Jon Russell Chief Medical Officer sell | $81k 4,221 shares | -2% | +119% from low-39% from high | |
| 13Weak | Stephen Feider Chief Financial Officer sell | $170k 10,000 shares | -6% | +90% from low-47% from high | |
| 13Weak | Stephen Feider Chief Financial Officer sell | $170k 10,000 shares | -6% | +90% from low-47% from high | |
| 10Weak | Christy Jones director sell | $21k 1,406 shares | -5% | +66% from low-54% from high | |
| 10Weak | Mark Hopman Chief Commercial Officer sell | $19k 1,258 shares | -1% | +66% from low-54% from high | |
| 16Weak | Christy Jones director sell | $39k 2,811 shares | -9% | +57% from low-57% from high | |
| 10Weak | Mark Hopman Chief Commercial Officer sell | $3,385 275 shares | -0% | +57% from low-57% from high | |
| 38Weak | Mark Hopman Chief Commercial Officer sell | $67k 5,329 shares | -4% | +44% from low-60% from high | |
| 37Weak | Mike Mensinger Chief Product Officer sell | $55k 4,378 shares | -2% | +44% from low-60% from high | |
| 46Moderate | Stephen Feider Chief Financial Officer sell | $84k 6,676 shares | -4% | +44% from low-60% from high | |
| 52Moderate | Sean Saint President & CEO sell | $213k 16,872 shares | -4% | +44% from low-60% from high | |
| 37Weak | Steven Jon Russell Chief Medical Officer sell | $53k 4,222 shares | -2% | +44% from low-60% from high | |
| 15Weak | Adam Lezack director sell | $21k 1,998 shares | -16% | +20% from low-67% from high | |
| 15Weak | Christy Jones director sell | $20k 1,998 shares | -13% | +20% from low-67% from high | |
| 19Weak | Mark Hopman Chief Commercial Officer sell | $88k 2,917 shares | -2% | +193% from low-10% from high | |
| 35Weak | Steven Jon Russell Chief Medical Officer sell | $30k 1,025 shares | -1% | +193% from low-10% from high | |
| 10Weak | Mark Hopman Chief Commercial Officer sell | $4,084 353 shares | -0% | +17% from low-64% from high | |
| 30Weak | Mark Hopman Chief Commercial Officer sell | $10k 834 shares | -1% | +29% from low-61% from high | |
| 30Weak | Mike Mensinger Chief Product Officer sell | $13k 1,064 shares | -1% | +29% from low-61% from high | |
| 37Weak | Stephen Feider Chief Financial Officer sell | $18k 1,428 shares | -1% | +29% from low-61% from high | |
| 46Moderate | Sean Saint President & CEO sell | $42k 3,384 shares | -1% | +29% from low-61% from high | |
| 30Weak | Steven Jon Russell Chief Medical Officer sell | $13k 1,026 shares | -1% | +29% from low-61% from high | |
| 11Weak | Mike Mensinger Chief Product Officer sell | $66k 2,200 shares | -3% | +223% from low-2% from high | |
| 16Weak | Mike Mensinger Chief Product Officer sell | $231k 7,800 shares | -9% | +201% from low-9% from high | |
| 24Weak | Stephen Feider Chief Financial Officer sell | $591k 20,000 shares | -32% | +201% from low-9% from high | |
| 35Weak | Mike Mensinger Chief Product Officer sell | $31k 1,063 shares | -1% | +193% from low-10% from high | |
| 43Moderate | Stephen Feider Chief Financial Officer sell | $42k 1,427 shares | -3% | +193% from low-10% from high | |
| 50Moderate | Sean Saint President & CEO sell | $96k 3,278 shares | -3% | +193% from low-10% from high | |
| 21Weak | Maria Palasis director sell | $42k 1,406 shares | -14% | +204% from low-6% from high | |
| 21Weak | Adam Lezack director sell | $42k 1,406 shares | -14% | +204% from low-6% from high | |
| 14Weak | Maria Palasis director sell | $38k 1,406 shares | -13% | +180% from low0% from high | |
| 14Weak | Adam Lezack director sell | $38k 1,406 shares | -13% | +180% from low0% from high | |
| 2Weak | Stephen Feider Chief Financial Officer sell | $108k 4,982 shares | -10% | +129% from low-16% from high | |
| 11Weak | Stephen Feider Chief Financial Officer sell | $312k 15,018 shares | -25% | +108% from low-23% from high | |
| 19Weak | Stephen Feider Chief Financial Officer sell | $209k 9,900 shares | -18% | +138% from low-3% from high | |
| 2Weak | Stephen Feider Chief Financial Officer sell | $2,100 100 shares | -0% | +108% from low-15% from high | |
| 20Weak | Mark Hopman Chief Commercial Officer sell | $371k 18,229 shares | -48% | +107% from low-16% from high | |
| 42Moderate | Stephen Feider Chief Financial Officer sell | $28k 1,462 shares | -3% | +96% from low-20% from high |
Planned sales
Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales
| Filed | Seller | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Oct 1, 2026 | MARK HOPMAN Officer | 2,660 0.01% of outstanding | $50k | Oct 1, 2026 | $1.4M |
| Sep 22, 2026 | CHRISTINA JONES Director | 8,942 0.02% of outstanding | $197k | Sep 22, 2026 | $21k |
| Sep 16, 2026 | MARK HOPMAN Officer | 28,119 0.06% of outstanding | $541k | Sep 16, 2026 | $813k |
| Sep 16, 2026 | MICHAEL MENSINGER Officer | 5,300 0.01% of outstanding | $102k | Sep 16, 2026 | $84k |
| Sep 9, 2026 | MARK HOPMAN Officer | 40,305 0.09% of outstanding | $779k | Sep 9, 2026 | $121k |
| Sep 3, 2026 | Sean Saint Officer | 5,641 0.01% of outstanding | $113k | Sep 3, 2026 | none |
| Sep 3, 2026 | Mark Hopman Officer | 5,327 0.01% of outstanding | $103k | Sep 2, 2026 | $89k |
| Sep 3, 2026 | Michael R. Mensinger Officer | 4,375 0.01% of outstanding | $85k | Sep 2, 2026 | $55k |
| Sep 3, 2026 | Stephen Feider Officer | 6,675 0.01% of outstanding | $130k | Sep 2, 2026 | $255k |
| Sep 3, 2026 | Sean Saint Officer, Director | 16,867 0.04% of outstanding | $327k | Sep 2, 2026 | $213k |
| Sep 3, 2026 | Steven Jon Russell Officer | 4,221 0.01% of outstanding | $82k | Sep 2, 2026 | $53k |
| Jun 29, 2026 | Stephen Feider Officer | 4,896 0.01% of outstanding | $83k | Jun 29, 2026 | $172k |
| Jun 26, 2026 | Stephen Feider Officer | 5,104 0.01% of outstanding | $87k | Jun 26, 2026 | $85k |
| Jun 24, 2026 | Mark Hopman Officer | 1,258 0.00% of outstanding | $19k | Jun 24, 2026 | $72k |
| Jun 24, 2026 | CHRISTINA JONES Director | 1,406 0.00% of outstanding | $19k | Jun 24, 2026 | $59k |
| Jun 4, 2026 | Mark Hopman Officer | 275 0.00% of outstanding | $3,385 | Jun 4, 2026 | $72k |
| Jun 4, 2026 | CHRISTINA JONES Director | 2,811 0.01% of outstanding | $35k | Jun 4, 2026 | $20k |
| Jun 3, 2026 | Mark Hopman Officer | 5,329 0.01% of outstanding | $68k | Jun 2, 2026 | none |
| Jun 3, 2026 | Michael R. Mensinger Officer | 4,378 0.01% of outstanding | $56k | Jun 2, 2026 | $13k |
| Jun 3, 2026 | Stephen Feider Officer | 6,676 0.01% of outstanding | $85k | Jun 2, 2026 | $18k |
| Jun 3, 2026 | Sean Saint Officer, Director | 16,872 0.04% of outstanding | $216k | Jun 2, 2026 | $42k |
| Jun 3, 2026 | Steven Jon Russell Officer | 4,222 0.01% of outstanding | $54k | Jun 2, 2026 | none |
| May 21, 2026 | ADAM LEZACK Director | 1,998 0.00% of outstanding | $20k | May 21, 2026 | none |
| May 21, 2026 | CHRISTINA JONES Director | 1,998 0.00% of outstanding | $20k | May 21, 2026 | none |
| Mar 4, 2026 | Mark Hopman Officer | 353 0.00% of outstanding | $4,084 | Mar 4, 2026 | $63k |
Transactions
The newest 50 of 197 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 1, 2026 | Mark Hopman Chief Commercial Officer | SOpen-market sale Common Stock10b5-1 | -370 | $18.96 | $7,015 | 56,109 | 8 d ago |
| Sep 22, 2026 | Christy Jones director | SOpen-market sale Common Stock10b5-1 | -6,430 | $23.00 | $148k | 19,564 | 20 d ago |
| Sep 9, 2026 | Mark Hopman Chief Commercial Officer | SOpen-market sale Common Stock10b5-1 | -35,994 | $18.46 | $665k | 88,033 | 25 d ago |
| Sep 16, 2026 | Mike Mensinger Chief Product Officer | SOpen-market sale Common Stock10b5-1 | -2,650 | $22.00 | $58k | 177,390 | 26 d ago |
| Sep 16, 2026 | Mark Hopman Chief Commercial Officer | SOpen-market sale Common Stock10b5-1 | -30,779 | $20.13 | $620k | 56,479 | 26 d ago |
| Sep 14, 2026 | Mark Hopman Chief Commercial Officer | SOpen-market sale Common Stock10b5-1 | -775 | $15.52 | $12k | 86,382 | 28 d ago |
| Sep 9, 2026 | Mark Hopman Chief Commercial Officer | SOpen-market sale Common Stock10b5-1 | -36,870 | $18.46 | $681k | 87,157 | 33 d ago |
| Sep 3, 2026 | Sean Saint President & CEO | SOpen-market sale Common Stock10b5-1 | -5,641 | $20.08 | $113k | 398,429 | 39 d ago |
| Sep 2, 2026 | Sean Saint President & CEO | SOpen-market sale Common Stock | -16,867 | $19.11 | $322k | 404,070 | 40 d ago |
| Sep 2, 2026 | Stephen Feider Chief Financial Officer | SOpen-market sale Common Stock | -6,675 | $19.11 | $128k | 159,378 | 40 d ago |
| Sep 2, 2026 | Mark Hopman Chief Commercial Officer | SOpen-market sale Common Stock | -5,327 | $19.11 | $102k | 124,027 | 40 d ago |
| Sep 2, 2026 | Mike Mensinger Chief Product Officer | SOpen-market sale Common Stock | -4,375 | $19.11 | $84k | 180,040 | 40 d ago |
| Sep 2, 2026 | Steven Jon Russell Chief Medical Officer | SOpen-market sale Common Stock | -4,221 | $19.11 | $81k | 169,628 | 40 d ago |
| Jun 26, 2026 | Stephen Feider Chief Financial Officer | MOption exercise Common Stock10b5-1 | +5,104 | $5.10 | $26k | 171,157 | Jul 2, 2026 |
| Jun 26, 2026 | Stephen Feider Chief Financial Officer | SOpen-market sale Common Stock10b5-1 | -5,104 | $17.05 | $87k | 166,053 | Jul 2, 2026 |
| Jun 29, 2026 | Stephen Feider Chief Financial Officer | MOption exercise Common Stock10b5-1 | +4,896 | $5.10 | $25k | 170,949 | Jul 2, 2026 |
| Jun 29, 2026 | Stephen Feider Chief Financial Officer | SOpen-market sale Common Stock10b5-1 | -4,896 | $17.03 | $83k | 166,053 | Jul 2, 2026 |
| Jun 26, 2026 | Stephen Feider Chief Financial Officer | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -5,104 | $0.00 | $0 | 44,591 | Jul 2, 2026 |
| Jun 29, 2026 | Stephen Feider Chief Financial Officer | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -4,896 | $0.00 | $0 | 39,695 | Jul 2, 2026 |
| Jun 26, 2026 | Stephen Feider Chief Financial Officer | MOption exercise Common Stock10b5-1 | +4,982 | $5.10 | $25k | 171,035 | Jun 30, 2026 |
| Jun 26, 2026 | Stephen Feider Chief Financial Officer | SOpen-market sale Common Stock10b5-1 | -5,104 | $17.05 | $87k | 165,931 | Jun 30, 2026 |
| Jun 29, 2026 | Stephen Feider Chief Financial Officer | MOption exercise Common Stock10b5-1 | +4,896 | $5.10 | $25k | 170,827 | Jun 30, 2026 |
| Jun 29, 2026 | Stephen Feider Chief Financial Officer | SOpen-market sale Common Stock10b5-1 | -4,896 | $17.03 | $83k | 165,931 | Jun 30, 2026 |
| Jun 26, 2026 | Stephen Feider Chief Financial Officer | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -4,982 | $0.00 | $0 | 44,713 | Jun 30, 2026 |
| Jun 29, 2026 | Stephen Feider Chief Financial Officer | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -4,896 | $0.00 | $0 | 39,817 | Jun 30, 2026 |
| Jun 24, 2026 | Mark Hopman Chief Commercial Officer | SOpen-market sale Common Stock10b5-1 | -1,258 | $15.01 | $19k | 129,354 | Jun 25, 2026 |
| Jun 24, 2026 | Christy Jones director | SOpen-market sale Common Stock10b5-1 | -1,406 | $15.00 | $21k | 25,994 | Jun 25, 2026 |
| Jun 4, 2026 | Christy Jones director | SOpen-market sale Common Stock10b5-1 | -2,811 | $14.00 | $39k | 27,400 | Jun 5, 2026 |
| Jun 4, 2026 | Mark Hopman Chief Commercial Officer | SOpen-market sale Common Stock10b5-1 | -275 | $12.31 | $3,385 | 130,612 | Jun 5, 2026 |
| Jun 2, 2026 | Stephen Feider Chief Financial Officer | SOpen-market sale Common Stock | -6,676 | $12.61 | $84k | 166,053 | Jun 3, 2026 |
| Jun 2, 2026 | Sean Saint President & CEO | SOpen-market sale Common Stock | -16,872 | $12.61 | $213k | 420,937 | Jun 3, 2026 |
| Jun 2, 2026 | Steven Jon Russell Chief Medical Officer | SOpen-market sale Common Stock | -4,222 | $12.61 | $53k | 173,849 | Jun 3, 2026 |
| Jun 2, 2026 | Mark Hopman Chief Commercial Officer | SOpen-market sale Common Stock | -5,329 | $12.61 | $67k | 130,887 | Jun 3, 2026 |
| Jun 2, 2026 | Mike Mensinger Chief Product Officer | SOpen-market sale Common Stock | -4,378 | $12.61 | $55k | 184,415 | Jun 3, 2026 |
| May 21, 2026 | Gerard J Michel director | AGrant or award Common Stock | +16,965 | $0.00 | $0 | 33,509 | May 26, 2026 |
| May 21, 2026 | Sean Carney director | AGrant or award Common Stock | +16,965 | $0.00 | $0 | 32,209 | May 26, 2026 |
| May 21, 2026 | Danny L. Dearen director | AGrant or award Common Stock | +16,965 | $0.00 | $0 | 32,209 | May 26, 2026 |
| May 21, 2026 | Maria Palasis director | AGrant or award Common Stock | +16,965 | $0.00 | $0 | 29,397 | May 26, 2026 |
| May 21, 2026 | Adam Lezack director | SOpen-market sale Common Stock10b5-1 | -1,000 | $9.95 | $9,950 | 11,432 | May 26, 2026 |
| May 21, 2026 | Christy Jones director | SOpen-market sale Common Stock10b5-1 | -1,998 | $9.95 | $20k | 13,246 | May 26, 2026 |
| May 21, 2026 | Adam Lezack director | AGrant or award Common Stock10b5-1 | +16,965 | $0.00 | $0 | 28,397 | May 26, 2026 |
| May 21, 2026 | Christy Jones director | AGrant or award Common Stock10b5-1 | +16,965 | $0.00 | $0 | 30,211 | May 26, 2026 |
| May 22, 2026 | Adam Lezack director | SOpen-market sale Comon Stock10b5-1 | -998 | $11.21 | $11k | 27,399 | May 26, 2026 |
| Dec 2, 2025 | Steven Jon Russell Chief Medical Officer | SOpen-market sale Common Stock | -1,025 | $29.34 | $30k | 178,071 | Mar 16, 2026 |
| Dec 2, 2025 | Mark Hopman Chief Commercial Officer | SOpen-market sale Common Stock10b5-1 | -856 | $29.34 | $25k | 138,277 | Mar 16, 2026 |
| Dec 4, 2025 | Mark Hopman Chief Commercial Officer | SOpen-market sale Common Stock10b5-1 | -2,061 | $30.66 | $63k | 136,216 | Mar 16, 2026 |
| Feb 27, 2026 | Steven Jon Russell Chief Medical Officer | AGrant or award Employee Stock Option (right to buy)derivative | +91,520 | $0.00 | $0 | 91,520 | Mar 13, 2026 |
| Feb 27, 2026 | Sean Saint President & CEO | AGrant or award Employee Stock Option (right to buy)derivative | +287,944 | $0.00 | $0 | 287,944 | Mar 13, 2026 |
| Feb 27, 2026 | Stephen Feider Chief Financial Officer | AGrant or award Employee Stock Option (right to buy)derivative | +110,342 | $0.00 | $0 | 110,342 | Mar 13, 2026 |
| Feb 27, 2026 | Mike Mensinger Chief Product Officer | AGrant or award Employee Stock Option (right to buy)derivative | +91,520 | $0.00 | $0 | 91,520 | Mar 13, 2026 |
50 of 197 rows shown.
Insiders
Everyone who has filed a Form 4 here.
- Sean Carneydirector
- Danny L. Dearendirector
- Stephen FeiderChief Financial Officer
- Mark HopmanChief Commercial Officer
- Christy Jonesdirector
- Adam Lezackdirector
- Gerard J Michelceo, officer, director
- Mike MensingerChief Product Officer
- Maria Palasisceo, president, officer, director
- Steven Jon RussellChief Medical Officer
- Sean SaintPresident & CEO
Questions about BBNX
Answered from the filings on this page, as of the latest one.
Are insiders buying BBNX?
As of Oct 5, 2026, SEC Form 4 filings show 0 open-market buys worth $0 by 0 insiders and 13 open-market sells worth $3.0M by 6 insiders at Beta Bionics, Inc. in the last 90 days, net -$3.0M. Only purchases (code P) and sales (code S) count; grants, option exercises and tax withholding do not.
Who was the last insider to trade BBNX on the open market?
Mark Hopman (Chief Commercial Officer) sold $7,015 of BBNX on Oct 1, 2026 and filed the Form 4 on Oct 5, 2026. InsiderTell scored 3 (weak), under a 10b5-1 plan, with 2 insiders on the same side within 14 days.
How many insiders file Form 4 at Beta Bionics, Inc.?
11 people have filed a Form 4 at Beta Bionics, Inc., among them Sean Carney (director), Danny L. Dearen (director), Stephen Feider (Chief Financial Officer). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.